Capecitabine: a novel agent for the treatment of solid tumors.
about
Clinical management of localized colon cancer with capecitabineCapecitabine in the management of colorectal cancerGene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cellsCalbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathwayGypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.Reduced NOV expression correlates with disease progression in colorectal cancer and is associated with survival, invasion and chemoresistance of cancer cellsmiR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axisClinical significance of prognostic and predictive markers in colorectal cancer.Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture.Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.Application of artificial neural network to investigate the effects of 5-fluorouracil on ribonucleotides and deoxyribonucleotides in HepG2 cells.Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancerA novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatmentEpigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population.Pharmacogenetics of chemotherapy efficacy in breast cancer.Capecitabine for the treatment of gastric cancer.Evaluation of the Cytotoxic Effects of Hyperthermia and 5-Fluorouracil Loaded Magnetic Nanoparticles on Human Colon Cancer Cell Line HT-29.Effect of Phyllanthus amarus Extract on 5-Fluorouracil-Induced Perturbations in Ribonucleotide and Deoxyribonucleotide Pools in HepG2 Cell Line.Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update.Lectin-directed enzyme activated prodrug therapy (LEAPT): Synthesis and evaluation of rhamnose-capped prodrugs.Functional mechanism of the enhancement of 5-fluorouracil sensitivity by TUSC4 in colon cancer cells.A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.A ruthenium-based 5-fluorouracil complex with enhanced cytotoxicity and apoptosis induction action in HCT116 cells.Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro.Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway.Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells.Mechanistic study of the anti-cancer effect of Gynostemma pentaphyllum saponins in the Apc(Min/+) mouse model.Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.Upregulation of let-7f-5p promotes chemotherapeutic resistance in colorectal cancer by directly repressing several pro-apoptotic proteins.
P2860
Q24611758-F835C2C3-C7CF-44B1-86FE-3A6CE098EA81Q24633039-95BD972D-0730-413D-B4A4-DA9BB7DA3F4EQ24802917-B9EF5A48-6D2E-42BE-8F5D-D34A0BED3C69Q28478265-27D9BA6A-B107-4DFE-8F48-48475AB52C8BQ28547966-994FAC7E-63C6-4A0B-890A-6759AB8A88D5Q33688607-9A660437-D011-46B9-8360-CA053797DAADQ33830016-E2B21BC9-90EB-40D2-8035-E038E97A0537Q34798558-D29B831E-0095-4E6A-88B0-24502500640EQ35452772-A307548F-3900-45AE-A276-816350664943Q35939528-B2D4D9C1-63DA-43B6-8C46-25C91242C300Q36249234-58605893-9C51-41FB-BF4F-9B4FE0329139Q36291296-33181E88-DDF9-4A87-A0F3-5D264DEA6B36Q36295263-62746ACB-9FBF-4538-BF88-14030436980BQ36845372-5D37F26D-FD0C-44A2-81EA-42EC2FF69AA6Q37085982-8763E636-E6AB-4293-8D2E-02DFFAE42D46Q37614489-B099176B-77AF-47C2-B29E-DC08FA99C8BBQ38003703-A6B52240-FDCC-4EE6-A5C8-CF8C4B89FD0DQ38608072-3224EA93-794E-4E25-8298-4CA13CB00113Q38742531-6DC75BE9-C34E-47D0-8418-D6A19BFED7B1Q38744412-5BC15EEB-B0DA-4A91-9DB1-DC5F7865D0C9Q42691338-92465D55-C913-41B3-8598-9649BBE5044DQ42837744-80380482-987B-49CD-BA21-38B88EDBEC94Q43147751-9A635176-E60F-420E-A71C-05C532BA8AD2Q45194039-E7CFD9BF-5514-4F56-A107-3AA9C0216475Q48267257-73D4C0ED-C9F4-409C-8AD2-9664DFE953A8Q48315153-349D8B1A-0BE1-42CC-86AC-33D852986BD0Q48629122-8D3A1B71-0433-4697-980A-C1F6E0FC7F31Q50976501-1BF57FAF-D022-4F3F-BE49-01029A4F8C8BQ53149885-B69B2055-5276-4604-B416-6C6926723F3CQ53529113-AAB81020-4F4E-4B5E-829B-BF03479971AAQ53596582-01A0FE6C-40D7-445A-AA27-CB51E2BC8D11Q54940306-2844269B-8848-4E03-9EB6-AAB6269F6E5B
P2860
Capecitabine: a novel agent for the treatment of solid tumors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Capecitabine: a novel agent for the treatment of solid tumors.
@ast
Capecitabine: a novel agent for the treatment of solid tumors.
@en
Capecitabine: a novel agent for the treatment of solid tumors.
@nl
type
label
Capecitabine: a novel agent for the treatment of solid tumors.
@ast
Capecitabine: a novel agent for the treatment of solid tumors.
@en
Capecitabine: a novel agent for the treatment of solid tumors.
@nl
prefLabel
Capecitabine: a novel agent for the treatment of solid tumors.
@ast
Capecitabine: a novel agent for the treatment of solid tumors.
@en
Capecitabine: a novel agent for the treatment of solid tumors.
@nl
P1433
P1476
Capecitabine: a novel agent for the treatment of solid tumors.
@en
P2093
P304
P356
10.1097/00001813-200109000-00001
P577
2001-09-01T00:00:00Z